IMUX — Immunic, Inc.
8 mentions in the last 24 hours · 0.03% of all mentions
Why people talked about IMUX (2026-11-06)
- Immunic announced plans for a Phase 3 trial of vidofludimus calcium for progressive multiple sclerosis following mixed Phase 2 results.
- The company held an R&D Day webinar on November 5, 2026, to present updates on its PMS research and development.
- A presentation slideshow regarding the development of vidofludimus calcium was released in connection with the webinar event.
| RSS Bundle | 3 | news |
| Bluesky | 2 | community |
| GDELT | 1 | news |
| Marketaux | 1 | news |
| SEC EDGAR 8-K | 1 | filings |